Amgen Inc on Tuesday said its second-quarter revenue fell 3per cent due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.
Amgen quarterly results beat estimates, but revenue dips 3per cent
